Literature DB >> 24452409

Operative failure in minimally invasive parathyroidectomy utilizing an intraoperative parathyroid hormone assay.

Sukhyung Lee1, Haengrang Ryu, Lilah F Morris, Elizabeth G Grubbs, Jeffrey E Lee, Nusrat Harun, Lei Feng, Nancy D Perrier.   

Abstract

BACKGROUND: Minimally invasive parathyroidectomy (MIP) is a targeted operation to cure primary hyperparathyroidism utilizing intraoperative parathyroid hormone monitoring (IOPTH). The purpose of this study was to quantify the operative failure of MIP.
METHODS: Utilizing institutional parathyroid surgery database, demographic, operative, and biochemical data were analyzed for successful and failed MIP. Operative failure was defined as <6 months of eucalcemia after operation.
RESULTS: Five hundred thirty-eight patients (96.6 %) had successful MIP with mean follow-up of 13 months, and 19 (3.4 %) had operative failure. The major cause of operative failure (11 of 19) was the result of surgeons' inability to identify all abnormal parathyroid glands. The remaining eight operative failures were the result of falsely positive IOPTH results. Eleven of 19 patients whose MIP had failed underwent a second parathyroid surgery. All but one of these patients achieved operative success, and 9 patients had missed multigland disease. Only 46 (8.3 %) of 557 patients had conversion to bilateral cervical exploration (BCE). Eighty percent of patients had more than 70 % IOPTH decrease, and all had successful operations. Patients with a marginal IOPTH decrease (50-59 %) had a treatment failure rate of 20 %.
CONCLUSIONS: The most common cause of operative failure in MIP utilizing IOPTH was the result of surgeons' failure to identify all abnormal parathyroid glands. Falsely positive IOPTH is rare, and a targeted MIP utilizing IOPTH can achieve an excellent operative success rate without routine BCE. Selective BCE on patients with marginal IOPTH decrease may improve surgical outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452409     DOI: 10.1245/s10434-013-3479-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Risk factors for treatment failure in surgery for primary hyperparathyroidism: the impact of change in surgical strategy and training procedures.

Authors:  Anders Rørbæk Madsen; Lars Rasmussen; Christian Godballe
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-05       Impact factor: 2.503

Review 2.  Persistent and recurrent hyperparathyroidism.

Authors:  Carole Guerin; Nunzia Cinzia Paladino; Aoife Lowery; Fréderic Castinetti; David Taieb; Fréderic Sebag
Journal:  Updates Surg       Date:  2017-04-22

3.  Successful minimally invasive surgery for primary hyperparathyroidism: influence of preoperative imaging and intraoperative parathyroid hormone levels.

Authors:  Gaëtan-Romain Joliat; Nicolas Demartines; Luc Portmann; Ariane Boubaker; Maurice Matter
Journal:  Langenbecks Arch Surg       Date:  2015-11-21       Impact factor: 3.445

4.  Current predictive models do not accurately differentiate between single and multi gland disease in primary hyperparathyroidism: a retrospective cohort study of two endocrine surgery units.

Authors:  O Edafe; E E Collins; C S Ubhi; S P Balasubramanian
Journal:  Ann R Coll Surg Engl       Date:  2017-09-15       Impact factor: 1.891

5.  Role of intraoperative PTH monitoring and surgical approach in primary hyperparathyroidism.

Authors:  Angela A Khan; Yasmin Khatun; Abigail Walker; Jaime Jimeno; Johnathan G Hubbard
Journal:  Ann Med Surg (Lond)       Date:  2015-08-28

Review 6.  Routine bilateral neck exploration and four-gland dissection remains unnecessary in modern parathyroid surgery.

Authors:  Nathaniel J Walsh; Brian T Sullivan; William S Duke; David J Terris
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-11-28

Review 7.  Sporadic multiple parathyroid gland disease--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Marcin Barczyński; Robert Bränström; Gianlorenzo Dionigi; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2015-11-05       Impact factor: 3.445

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.